• stage 1: disease present but without complications • stage 2: disease causing local or minor effects • stage 3: disease causing major or systemic effects • stage 4: disease is life threatening.
The Kidney Disease Outcomes Quality Initiative (KDOQI)/ Kidney Disease: Improving Global Outcomes (KDIGO) system of staging CKD is unorthodox and its use can be misleading in clinical practice. 1 • It has five stages, the first two of which are indistinguishable in clinical practice promoting what should be stage 2 (local or minor effects) to stage 3 (a disease causing major or systemic effects).
• Staging relies largely on a measurement of kidney function, the glomerular filtration rate (GFR), acting as a surrogate for the presence of kidney disease. The normal range of GFR cited is incorrect and not congruent with population measurements. The cut-offs for the stages are fixed and do not relate consistently to clinical consequences. 2 • The measurement used, estimated (e)GFR, is imprecise so subjects are frequently staged incorrectly.
• Patients in stages 1 to 3 are not homogeneous.
• It uses the word 'disease' loosely. This has been recognised by a number of authors and authorities, including the National Institute for Health and Clinical Excellence (NICE), some of whom have suggested modifications. [3] [4] [5] [6] A return to orthodox staging is being proposed. 7 Evidence of CKD would require that there be specific permanent pathology affecting the kidney with existing or potential threats to the health of the individual as a result. It should recognise that evidence of disease will usually be both structural (including imaging and/or pathology) and based on laboratory testing for signs of kidney damage (such as macro-proteinuria and haematuria or both) and in the later stages, functional (eg GFR related). The degree of reduction in function should be used for staging severity of established CKD not diagnosing CKD. Any eGFR value used for staging should be referenced to age, gender and ethnicity percentiles and the requirement for persistence of the eGFR abnormality/kidney damage for three months or more should be retained. 8 The term 'chronic renal failure/insufficiency' (CRF/I) should also be retained to mean the state in which there is a reduction in overall kidney function, such that there are defects in kidney-dependent homeostasis causing clinical and metabolic consequences in proportion to the severity of the reduction.
Stage 1 CKD would be applied to the early form of structural disease identified by histology, imaging or inferred from laboratory evidence of kidney damage including, for example, persistent macro-albuminuria, but without any associated reduction in renal function. The eGFR should be Ͼ5th percentile. Stage 2 CKD would also require evidence of overt kidney damage but in addition a reduction in kidney function (eGFR Ͻ5th percentile). For consistency with the KDOQI/KDIGO system the threshold separating stage 2 CKD from the new stage 3 CKD could arbitrarily be an eGFR of Ͻ30 ml/min/1.73m 2 . Evidence of a clinically relevant complication or consequence of reduced kidney function (eg anaemia) would promote the patient to stage 3 CKD. This stage would include patients in whom the eGFR lay between 15 and 30 ml/min/1.73m 2 . Evidence of kidney injury would almost certainly be present as would metabolic, endocrine, hematologic and cardiovascular complications of renal insufficiency. This higher stage takes account of the higher risk of such patients progressing to the new stage 4 CKD and even to the necessity for eventual renal replacement therapy.
Stage 4 CKD would only require that the eGFR be less than 15 ml/min/1.73m 2 , a level of GFR below which it is generally accepted there is a significant risk to the life and health of the patient requiring immediate attention. (Commonsense allows one to infer the presence of structural disease and complications). Stage 5 CKD would be applied to patients receiving regular renal replacement therapy in the form of dialysis. (Patients with functioning renal transplants probably require a separate system or nomenclature, possibly using a modifying term for stages 1 to 4 CKD.)
Subjects with an eGFR Ͻ5th percentile for age, gender and ancestry but Ͼ30ml/min/1.73m 2 and without any evidence of Chronic kidney disease: definition and staging -an orthodox view CG Winearls structural renal damage (ie normal imaging, no urinary abnormalities) and no evidence of renal function-related complications should not be described as having CKD but as having 'reduced kidney function of uncertain significance'. This description will accommodate a significant minority of the elderly, subjects who have undergone unilateral nephrectomy and those who have a non-renal cause of a reduced GFR, such as congestive heart failure.
There is resistance to refining the existing CKD staging systems on the grounds that they are now widely used and any change will cause confusion. This would be a small price to pay for perpetuating a flawed system and irreversibly embedding it into clinical practice for future generations of doctors. It is also argued that the CKD/eGFR construct is important in assessing CVD risk. Stage 3 CKD (as presently defined) does not seem to universally carry such a risk. 9 Moreover, risk factors are not the same as diseases. 10 In the same way that the geocentric view of the universe gave way to the heliocentric, this nephrocentric construct needs to be changed to a 'vasculocentric' one. Attention to, and research into, CKD should not be diminished by such a change but it would spare nephrology the risk of accusations of overplaying its hand and misdiagnosing large numbers of relatively healthy individuals as having advanced stages of a chronic disease (Table 1) . 
